Yalcin, A. D. Et Al. 2012. Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment. MEDICAL SCIENCE MONITOR , vol.18, no.3 .

Yalcin, A. D., Bisgin, A., Kargi, A., & Gorczynski, R. M., (2012). Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment. MEDICAL SCIENCE MONITOR , vol.18, no.3.

Yalcin, Arzu Et Al. "Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment," MEDICAL SCIENCE MONITOR , vol.18, no.3, 2012

Yalcin, Arzu D. Et Al. "Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment." MEDICAL SCIENCE MONITOR , vol.18, no.3, 2012

Yalcin, A. D. Et Al. (2012) . "Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment." MEDICAL SCIENCE MONITOR , vol.18, no.3.

@article{article, author={Arzu Didem Yalcin Et Al. }, title={Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment}, journal={MEDICAL SCIENCE MONITOR}, year=2012}